This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $3,004.53 contract is for the delivery of Ozurdex 0.7 mg implants, a specialty ophthalmic medication.
The award is part of DMS Pharmaceutical Group's larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999 and running through December 31, 2025. This single-award IDC allows the DLA to issue firm fixed-price delivery orders for a wide range of pharmaceutical products to support the recurring medical supply needs of military health facilities worldwide.
The contract does not have a set-aside designation. DMS Pharmaceutical Group is a key supplier in the federal pharmaceutical supply chain, providing a comprehensive range of branded, generic, and specialty medications, as well as medical consumables, to the Department of Defense and Department of Veterans Affairs.
Generated 12/26/24, 9:04 AM